Granulocyte-macrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients.

摘要: Abstract We conducted a clinical trial of human recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) in leukopenic patients with acquired immunodeficiency syndrome (AIDS) and analyzed neutrophil function before, during, after vivo administration rGM-CSF. Prior to GM-CSF infusion, AIDS patients' superoxide generation antibody-dependent cell-mediated cytotoxicity were enhanced normally by vitro exposure GM-CSF. Neutrophil phagocytosis intracellular killing Staphylococcus aureus also normal the majority these patients. Two patients, however, had discrete functional defects: one killing. During period abnormalities corrected. The number circulating neutrophils increased all treated dose-dependent manner. Neutrophils produced response functioned there was evidence for priming activation vivo. We conclude that treatment leads production functionally active neutrophils, suggesting therapeutic potential impaired host defense.